Prenatal screening
G-NIPT® Basic
Screening for trisomy 21, 18, and 13; sex chromosome aneuploidies; fetal sex confirmation; and other autosomal trisomies.
- Lab
- GC Genome
- Method
- NGS
- Specimen
- Streck cfDNA tube
- TAT
- ~17 days incl. shipping
Clinical test menu
Browse AC testing pathways by indication rather than by laboratory catalog: prenatal screening, oncology, hemato-oncology, hereditary cancer, rare disease, reproductive genetics, preventive genomics, and wellness-oriented tests.
Tests are intended to be ordered and interpreted in consultation with a qualified physician. Turnaround times are quoted end to end — the reference laboratory’s processing time plus courier transit from Jordan, 5 days to Korea and 8 days to the United States. They remain indicative and may vary with specimen quality, shipment timing, and laboratory workflow.
Menu overview
49
written up in detail
8
browse categories
49 tests shown
5 tests
NIPT and non-invasive prenatal screening options from maternal blood.
View clinical information →Prenatal screening
Screening for trisomy 21, 18, and 13; sex chromosome aneuploidies; fetal sex confirmation; and other autosomal trisomies.
Prenatal screening
Core non-invasive prenatal screening for trisomy 21, 18, and 13, sex chromosome aneuploidies, and fetal sex confirmation.
Prenatal screening
Expanded NIPT screening covering all autosomes, sex chromosome aneuploidies, fetal sex, selected CNVs, and CNVs larger than 7 Mb.
Prenatal screening
Non-invasive prenatal screening option performed from maternal EDTA whole blood.
Prenatal screening
Expanded NIPT screening with all autosomes, sex chromosome aneuploidies, 143 microdeletions, fetal sex, and a focused pathogen panel.
4 tests
Tumor profiling, HRD, and liquid biopsy pathways for solid cancers.
View clinical information →Tumor profiling
Broad solid tumor profiling including hotspot mutations, full-exon coverage, CNV, RNA fusion analysis, MSI, and TMB.
Tumor profiling
DNA-focused solid tumor profiling from FFPE tissue when RNA analysis is not required or not feasible.
Tumor profiling
Homologous recombination deficiency testing from tumor tissue.
Tumor profiling
Plasma cell-free DNA profiling covering SNV/indel, CNV, RNA fusion, TMB, and MSI where tissue is unavailable or insufficient.
5 tests
NGS panels for acute leukemia, lymphoma, MDS/MPN, and plasma-cell neoplasms.
View clinical information →Hematologic malignancy
Molecular profiling panel for acute lymphoblastic leukemia.
Hematologic malignancy
Molecular profiling panel for acute myeloid leukemia and related clinical questions.
Hematologic malignancy
A 60-gene panel for molecular characterization of lymphoid malignancies.
Hematologic malignancy
Molecular profiling for myelodysplastic and myeloproliferative neoplasms.
Hematologic malignancy
Molecular testing panel for plasma-cell neoplasms.
2 tests
Germline cancer predisposition testing and family-risk assessment.
View clinical information →Hereditary cancer
A 98-gene germline panel covering inherited cancer predisposition across 23 cancer types.
Hereditary cancer
Focused hereditary cancer panel for breast, ovarian, and other women's cancer risk indications.
14 tests
Exome, genome, and targeted testing for rare or undiagnosed disease.
View clinical information →Exome / genome sequencing
Genome sequencing for a proband with suspected rare or undiagnosed genetic disease.
Exome / genome sequencing
Trio-based genome sequencing for rare disease evaluation.
Targeted rare disease
Targeted familial variant testing using Sanger sequencing.
Targeted rare disease
FMR1 repeat-expansion screening for Fragile X syndrome indications.
Targeted rare disease
SMN1/SMN2 dosage analysis for spinal muscular atrophy.
Exome / genome sequencing
Whole exome sequencing for a proband with suspected rare genetic disease.
Exome / genome sequencing
Whole exome sequencing through GC Genome for proband-only evaluation.
Exome / genome sequencing
Trio whole exome sequencing through GC Genome.
Exome / genome sequencing
Whole genome sequencing for broad rare disease assessment.
Clinical genetics
Exome sequencing with interpretation against GeneDx's rare-disease dataset. Available proband-only, duo, or trio (patient plus one or both biological parents), with trio generally improving yield and reducing uncertain results. Holds FDA Breakthrough Device designation.
Clinical genetics
Genome sequencing covering coding and non-coding regions, used where exome has been uninformative or a structural or non-coding cause is suspected. Holds FDA Breakthrough Device designation.
Clinical genetics
Accelerated genome sequencing for critically ill infants and children in the NICU or PICU, where a molecular diagnosis may change management within the admission. Requires coordination before collection — do not order this pathway without confirming the timeline with AC first.
Clinical genetics
Tests a relative for a specific variant already identified in the family, or confirms a variant reported elsewhere. Requires the prior report identifying the variant.
Clinical genetics
Clinical exome sequencing of the patient and one biological parent for suspected monogenic disease.
6 tests
Chromosomal microarray and reproductive genetic testing pathways.
View clinical information →Chromosomal analysis
Chromosomal microarray for developmental delay, autism spectrum disorder, congenital anomalies, and related indications.
Chromosomal analysis
All-chromosome deletion/duplication analysis for products of conception and pregnancy loss evaluation. Confirm specimen type and collection requirements with the reference laboratory before sampling.
Clinical genetics
Exome sequencing for a fetus with structural anomalies on ultrasound where karyotype and microarray have been uninformative. Interpreted against GeneDx's prenatal exome dataset. Requires pre-test counselling and coordination — confirm specimen route and timeline with AC before the procedure.
Chromosomal analysis
SNP array screening for 200–300 chromosomal abnormalities associated with rare disease.
Chromosomal analysis
Bebegene Basic coverage with an extended panel of microdeletion and microduplication regions.
Chromosomal analysis
The widest Bebegene configuration, covering around 1,001 microdeletion regions.
7 tests
Predictive health screening, pharmacogenetics, and disease-risk genomics.
View clinical information →Cancer early detection
Multi-cancer early detection from cfDNA; includes five cancer types for males and six cancer types for females, including ovarian cancer.
Preventive genomics
Polygenic risk assessment across 45 disease categories for females, including 14 cancer types.
Preventive genomics
Polygenic risk assessment across 44 disease categories for males, including neurological, cardiovascular, metabolic, and cancer risks.
Preventive genomics
Genomic screening focused on inherited cancer predisposition and risk stratification.
Preventive genomics
A 40-gene screen covering 15 disease types, including hereditary arrhythmia syndromes.
Pharmacogenetics
Ten-gene pharmacogenetic panel predicting response across 34 drugs used in cardiometabolic, gastrointestinal, inflammatory, and other conditions.
Preventive genomics
Telomere-related risk assessment from peripheral blood.
6 tests
Wellness-oriented genomic packages for lifestyle, predisposition, and personal insights.
Wellness genomics
Wellness genomics covering healthcare, dietary, nutrition, fitness, beauty, ancestry, and other options.
Wellness genomics
SNP array covering selected cancer, common disease, and ophthalmic disease predisposition markers.
Wellness genomics
Bundled multi-panel array package including Momcare, Gene2me Plus, MyEyeGene, Skincare, Ancestry, and more.
Wellness genomics
Genetic predisposition screening across neuropsychological, dermatological, respiratory, refractive, nutritional, athletic, and chronic-condition markers.
Wellness genomics
Predisposition testing for macular degeneration, glaucoma, retinitis pigmentosa, keratoconus, and severe dry eye syndrome.
Clinical genetics
DNA methylation analysis reporting biological age against chronological age.
Need guidance?
Check the full test menu first — 651 further assays our partners run. If it is not there either, tell us the clinical question and specimen type and AC can help confirm the best pathway, sample requirements, and next steps.